Abnormal levels of age-elastin derived peptides in sera of diabetic patients with arterial hypertension

Central European Journal of Immunology

Volumn 39, Issue 3, 2014, Pages 345-351

  Nikolov, Asparuh ^a   Tsinlikov, Ivan ^a   Nicoloff, George ^a   Tsinlikova, Ivanka ^a   Blazhev, Alexander ^a   Garev, Antoan ^a  

^a MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

Author keywords

AGEs; Arterial hypertension; Diabetic microvascular complications; Elastin; ELISA

Indexed keywords

AGE ELASTIN DERIVED PEPTIDE; BIOLOGICAL MARKER; ELASTIN; INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD VESSEL WALL; BODY MASS; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

EID: 84907973444     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2014.45946     Document Type: Article

References (33)

1. Brownlee M (2005): The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54: 1615-1625.
2. Brownlee M (2009): Diabetic complications: Pathobiology of hyperglycemic damage and potential impact on treatment. Intertratiol expert workshop. Rome, Italy 2008: 1-8.
3. Baumann M (2012): Role of advanced glycation end products in hypertension and cardiovascular risk: Human studies. J Am Soc Hypertens 6: 427-435. DOI: 10.1016/j.jash.2012.10.005.
4. McNulty M, Mahmud A, Feely J (2007): Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 20: 242-247.
5. Hartog JW, van de Wal RM, Schalkwijk CG, et al. (2010): Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur J Heart Fail 12: 397-403. DOI: 10.1093/eurjhf/hfq001.
6. Hayase F, Nagaraj RH, Miyata S, et al. (1989): Aging of proteins: Immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 263: 3758-3764.
7. Makita Z, Vlassara H, Cerami A, Bucala R (1992): Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138.
8. Brownlee M, Cerami A, Vlassara H (1988): Advanced glycation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321.
9. Makino H, Shikata K, Hironaka K (1995): Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 48: 517-526.
10. Brownlee M (1994): Glycation and diabetic complications. Diabetes 43: 836-841.
11. Hammes HP, Weiss A, Hess S, et al. (1996): Modification of vitronectin by advanced glycation alters functional properties in vitro and in diabetic retina. Lab Invest 75: 325-338.
12. Vlassara H, Bucala R, Striker L (1994): Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138-151.
13. Murata T, Nagai R, Ishibashi T, et al. (1997): The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40: 764-769.
14. Horiuchi S, Araki N, Morino Y (1991): Immunological approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem 266: 7329-7332.
15. Rosenbloom J, Abrams WR, Mecham R (1993): Extracellular matrix 4: The elastic fiber. FASEB J 7: 1208-1218.
16. Baydanoff S, Nicoloff G, Alexiev C (1987): Age-related changes in the level of elastin-derived peptides in serum from normal and atherosclerotic human subjects. Atherosclerosis 66: 163-168.
17. Frette C, Wei SM, Neukirch F, et al. (1992): Relation of serum elastin peptide concentration to age, FEV1, smoking habits, and protease inhibitor phenotype: An epidemiological study in working men. Thorax 47: 937-942.
18. Baydanoff S, Nicoloff G, Alexiev Ch (1995): The possible role of the immune system in elastin turnover under physiological conditions. Cor et Vasa 37: 253-255.
19. Baydanoff S, Nicoloff G, Alexiev C (1987): Age-related changes in anti-elastin antibodies in serum from normal and atherosclerotic human subjects. Atherosclerosis 63: 267-271.
20. Fulop T, Wei S, Robert L, Jacob MP (1990): Determination of elastin peptides in normal and atherosclerotic human sera by ELISA. Clin Physiol Biochem 8: 273-278.
21. Colburn K, Kelly G, Malto M, Sandberg L, Boucek R (1992): Serum anti-tropo: Anti-alpha-elastin antibody ratio assessing elastin turnover in scleroderma. Clin Rheum 11: 206-210.
22. Labat-Robert J, Robert L (1988): Aging of the extracellular matrix and its pathology. Exp Gerontol 23: 5-18.
23. UKPDS (United Kingdom Prospective Diabetes Study Group) (1998): Intensive blood glucose control with sulphonylureas or insulin and risk of complications in patients with type 2 diabetes mellitus. Lancet 352: 837-853.
24. Bouissou H, Pieraggi MT, Julian M (1985): Aging of elastic tissue in skin and arteries. In: Robert L, Murata K, Nagai Y (eds.). Degenerative diseases of connective tissue and aging. Kodansha, Tokyo: 203-216.
25. Robert C, Lesty C, Robert AM (1988): Ageing of the skin: Study of elastic fiber network. Modifications by computerized image analysis. Gerontology 34: 291-296.
26. Cox CS (1991): Roles of Maillard reactions in diseases. HMSO, London.
27. Stone PJ (2000): Potential use of collagen and elastin degradation markers for monitoring liver fibrosis in schistosomiasis. Acta Trop 77: 97-99.
28. Robert L, Jacob MP, Fülop T, et al. (1989): Elastonectin and the elastin receptor. Pathol Biol (Paris) 37: 736-741.
29. Kennedy L (1992): Glycation of immunoglobulins and serum proteins. In International Textbook of Diabetes Mellitus. 2nd ed. Alberti KGMM, de Fronzo RA, Keen H, Zimmet P (eds.). John Wiley, Chichester: 985-1007.
30. Singh R, Barden A, Mori T, Beilin L (2001): Advanced glycation end-products: A review. Diabetologia 44: 129-146.
31. Vasdev S, Gill V, Singal P (2007): Role of advanced glycation end products in hypertension and atherosclerosis: Therapeutic implications. Cell Biochem Biophys 49: 48-63.
32. Turk Z, Sesto M, Scodlar J, et al. (2003): Products of advanced glycation in patients with type 2 diabetes and vascular disease. Ann Clin Biochem 40: 552-559.
33. Medof ME, Oger JJ (1982): Competitions for immune complexes by red cells in human blood. J Clin Lab Immunol 7: 7-13.